Entity family

Browse institutions

Universities, hospitals, research centres, networks, and public bodies. Examples include universities, NHS trusts, research networks.

2articles mentioning institutions

2institution mentions

1distinct institutions extracted

0%of mentions human-reviewed

Active filtersEntity: NAPOLI-1 trial ×

NAPOLI-1 trial

This institution is selected. Its supporting articles are shown below.

NAPOLI-1 trial2

Articles mentioning NAPOLI-1 trial

2 articles · page 1 of 1

4CPS-013 Effectiveness and safety of liposomal irinotecan in the treatment of metastatic pancreatic cancer in routine clinical practice

ejhpharm · abstract · 2026-03-18 · 1 matching annotations

84.0%

NAPOLI-1 trial gemcitabine-nabpaclitaxel Metastatic pancreatic cancer liposomal irinotecan NALIRI fluorouracil mPC folinic acid

…vance The effectiveness of NALIRI was comparable to that of the NAPOLI-1 trial. NALIRI showed a high incidence of adverse effects, which in ma…

Actionable mutations in pancreatic cancer: where targeted therapies are making a difference

bmjgast · abstract · 2025-11-27 · 1 matching annotations

78.7%

NAPOLI-1 trial pembrolizumab 5-fluorouracil leucovorin adagrasib zenocutuzumab Pancreatic ductal adenocarcinoma (PDAC)liposomal irinotecan daraxonrasib conventional chemotherapy

…an yield outcomes that meet or exceed the benchmarks set by the NAPOLI-1 trial (liposomal irinotecan plus 5-fluorouracil and leucovorin), with…